Detalles de la búsqueda
1.
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).
Clin Exp Rheumatol
; 37(6): 937-945, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31025930
Resultados
1 -
1
de 1
1
Próxima >
>>